个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Fast construction of SARS-CoV-2 associated plasmid library using parallel cloning method

| 认领 | 导出 | |

文献详情

资源类型：
Pubmed体系：
作者：
Meng Fan[1] * ; Guo Jiao[1] ; Wang Shan[1] ; Zhang Changhui[2] ; Li Xuehui[2] ; Chen Yanjuan[2] ; Shi Qiuli[2] ; Shao Liang[2] ; Zhang Rundong[2] ; Wang Ganggang[3] ; Su Dan[2,4,*1] ;
机构： [1]Jujing-Chengdu Biotech, Chengdu, Sichuan, PR China. [2]State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, Chengdu, Sichuan, PR China. [3]Key Laboratory of Environmental and Applied Microbiology, Chengdu Institute of Biology, Chinese Academy of Sciences, PR China. [4]Tianjin International Joint Academy of Biotechnology and Medicine, Tianjin, PR China.
出处：
DOI： 10.1016/j.heliyon.2023.e17364
ISSN：

关键词： SARS-CoV-2 COVID-19 Plasmids library Parallel cloning

摘要：
The COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has had a significant impact on global health. To address the urgent need for plasmids containing SARS-CoV-2 sequences in research, we have developed a high-throughput FastCloning platform for the construction of associated plasmids. Our platform uses a FastCloning method to construct a plasmid library from 29 ORFs of the virus and 20 commonly used vectors in the lab. The library contains 536 recombinant vectors, with a highly positive clone success rate of 92.4%. Our study provides a rapid and efficient approach to constructing a large plasmid library for SARS-CoV-2 research.© 2023 The Authors.

基金：
Research Fund on COVID-19 of Sichuan Province {2020YFS0010}, Sichuan Province Science and Technology Support Program {2022NSFSC0008}, Natural Science Foundation of Tianjin-Science and Technology Correspondent Project {19YFZCSN00470}
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类 | 3 区 综合性期刊
小类 | 3 区 综合性期刊
最新[2023]版：
大类 | 3 区 综合性期刊
小类 | 3 区 综合性期刊
第一作者：
第一作者机构： [1]Jujing-Chengdu Biotech, Chengdu, Sichuan, PR China.
通讯作者：
通讯机构： [2]State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, Chengdu, Sichuan, PR China. [4]Tianjin International Joint Academy of Biotechnology and Medicine, Tianjin, PR China. [*1]State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, Chengdu, Sichuan, PR China
推荐引用方式(GB/T 7714)：
Meng Fan,Guo Jiao,Wang Shan,et al.Fast construction of SARS-CoV-2 associated plasmid library using parallel cloning method[J].Heliyon.2023,9(6):e17364.doi:10.1016/j.heliyon.2023.e17364.
APA：
Meng Fan,Guo Jiao,Wang Shan,Zhang Changhui,Li Xuehui...&Su Dan.(2023).Fast construction of SARS-CoV-2 associated plasmid library using parallel cloning method.Heliyon,9,(6)
MLA：
Meng Fan,et al."Fast construction of SARS-CoV-2 associated plasmid library using parallel cloning method".Heliyon 9..6(2023):e17364

相关文献

[1]环境卫生与监测：新常态下防控COVID-19的双轮效应思考 [2]Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19. [3]Animal models for SARS-CoV-2 infection and pathology. [4]An integrative analysis identifying transcriptional features and key genes involved in COVID-19. [5]A COVID-19 vaccine candidate composed of the SARS-CoV-2 RBD dimer and Neisseria meningitidis outer membrane vesicles. [6]Discovery and Nanosized Preparations of (S,R)-Tylophorine Malate as Novel anti-SARS-CoV-2 Agents. [7]Can We Use mTOR Inhibitors for COVID-19 Therapy? [8]SARS-CoV-2 Infection Induces Psoriatic Arthritis Flares and Enthesis Resident Plasmacytoid Dendritic Cell Type-1 Interferon Inhibition by JAK Antagonism Offer Novel Spondyloarthritis Pathogenesis Insights [9]Multidisciplinary recommendations for the management of CAR-T recipients in the post-COVID-19 pandemic era [10]Influence of Cigarettes and Alcohol on the Severity and Death of COVID-19: A Multicenter Retrospective Study in Wuhan, China(Open Access)

资源点击量：53699 今日访问量：0 总访问量：4607 更新日期：2025-02-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号